Biotest Aktiengesellschaft BIO3.VI Stock
Biotest Aktiengesellschaft Price Chart
Biotest Aktiengesellschaft BIO3.VI Financial and Trading Overview
| Biotest Aktiengesellschaft stock price | 28.9 EUR |
| Previous Close | 31.2 EUR |
| Open | 31.4 EUR |
| Bid | 0 EUR x 0 |
| Ask | 31.6 EUR x 0 |
| Day's Range | 31.4 - 31.4 EUR |
| 52 Week Range | 30.2 - 36.3 EUR |
| Volume | 0 EUR |
| Avg. Volume | 4 EUR |
| Market Cap | 1.48B EUR |
| Beta (5Y Monthly) | 0.288122 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 3.2 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 6, 2022 |
| 1y Target Est | N/A |
BIO3.VI Valuation Measures
| Enterprise Value | 1.78B EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.8633413 |
| Price/Book (mrq) | 3.4422276 |
| Enterprise Value/Revenue | 3.448 |
| Enterprise Value/EBITDA | 240.243 |
Trading Information
Biotest Aktiengesellschaft Stock Price History
| Beta (5Y Monthly) | 0.288122 |
| 52-Week Change | -11.048% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 36.3 EUR |
| 52 Week Low | 30.2 EUR |
| 50-Day Moving Average | 31.38 EUR |
| 200-Day Moving Average | 33.36 EUR |
BIO3.VI Share Statistics
| Avg. Volume (3 month) | 4 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 19.79M |
| Float | 19.98M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 2.16% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | 15.00% |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -9.12% |
| Operating Margin (ttm) | -4.69% |
| Gross Margin | 23.84% |
| EBITDA Margin | 1.43% |
Management Effectiveness
| Return on Assets (ttm) | -1.32% |
| Return on Equity (ttm) | -12.99% |
Income Statement
| Revenue (ttm) | 517.4M EUR |
| Revenue Per Share (ttm) | 13.01 EUR |
| Quarterly Revenue Growth (yoy) | 1.09% |
| Gross Profit (ttm) | N/A |
| EBITDA | 7.43M EUR |
| Net Income Avi to Common (ttm) | -47200000 EUR |
| Diluted EPS (ttm) | -1.18 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 68M EUR |
| Total Cash Per Share (mrq) | 1.77 EUR |
| Total Debt (mrq) | 650.9M EUR |
| Total Debt/Equity (mrq) | 185.39 EUR |
| Current Ratio (mrq) | 4.613 |
| Book Value Per Share (mrq) | 9.122 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -97800000 EUR |
| Levered Free Cash Flow (ttm) | -125050000 EUR |
Profile of Biotest Aktiengesellschaft
| Country | Austria |
| State | N/A |
| City | Dreieich |
| Address | Landsteinerstrasse 5 |
| ZIP | 63303 |
| Phone | 49 61 03 801 0 |
| Website | https://www.biotest.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2228 |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
Q&A For Biotest Aktiengesellschaft Stock
What is a current BIO3.VI stock price?
Biotest Aktiengesellschaft BIO3.VI stock price today per share is 28.9 EUR.
How to purchase Biotest Aktiengesellschaft stock?
You can buy BIO3.VI shares on the Vienna exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Biotest Aktiengesellschaft?
The stock symbol or ticker of Biotest Aktiengesellschaft is BIO3.VI.
Which industry does the Biotest Aktiengesellschaft company belong to?
The Biotest Aktiengesellschaft industry is Biotechnology.
How many shares does Biotest Aktiengesellschaft have in circulation?
The max supply of Biotest Aktiengesellschaft shares is 48.47M.
What is Biotest Aktiengesellschaft Price to Earnings Ratio (PE Ratio)?
Biotest Aktiengesellschaft PE Ratio is 9.03125000 now.
What was Biotest Aktiengesellschaft earnings per share over the trailing 12 months (TTM)?
Biotest Aktiengesellschaft EPS is 3.2 EUR over the trailing 12 months.
Which sector does the Biotest Aktiengesellschaft company belong to?
The Biotest Aktiengesellschaft sector is Healthcare.